

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **POSITIVE PROFIT ALERT**

This announcement is made by Lee's Pharmaceutical Holdings Limited (the "**Company**"), together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the Company that, based on the preliminary assessment of the Group's unaudited financial information currently available to the Board, the Group is expected to record an unaudited net profit attributable to the Shareholders in the range of HK\$58 million to HK\$63 million for the six months ended 30 June 2024 as compared with approximately HK\$16 million recorded for the six months ended 30 June 2023.

The expected improvement of the Group's interim results was mainly attributable to, among other things, (i) the sales growth of the products included in the updated National Reimbursement Drug List such as Treprostinil Injection (芮旋爾®), Teglutik®, and Trittico®, along with those selected in the volume-based procurement program, like Nadroparin Calcium Injection (立騰菁®), have significantly improved sales revenue during the period under review; (ii) decreased research and development expenses by approximately HK\$14.7 million through the optimisation of research and development portfolio; and (iii) cost savings resulting from the initiatives in the Group's management optimisation.

\* For identification purpose only

The Company is in the course of finalising the interim results of the Group for the six months ended 30 June 2024. The information contained herein is only a preliminary assessment by the Board based on information currently available including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024, which have not been confirmed, reviewed or audited by the auditors of the Company, and is neither constitutes a forecast of subsequent quarters nor an indication of the annual financial performance of the Group for the financial year 2024. The financial information of the Group for subsequent quarters will be subject to, among other things, the business performance of the Group by then.

The interim results announcement of the Company for the six months ended 30 June 2024 is expected to be published by the end of August 2024 in full compliance with the requirements under the Listing Rules.

**Shareholders and potential investors are advised to exercise cautions when dealing in the shares of the Company.**

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 4 August 2024

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company; Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie Chin are non-executive directors of the Company; and Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.*